A blood test correctly identified 87% of stage 1 and 2 pancreatic cancers, according to a study published Sept. 16 in Nature Medicine.
For the study, researchers from Duarte, Calif.-based City of Hope tested the PANXEON liquid biopsy in nearly 1,800 patients across the U.S., Europe and Asia.
The test identifies three biomarkers — circulating microRNAs, exosomal microRNAs and the protein CA19-9 — and assigns a single AI-generated pancreatic cancer risk score.
The test’s false-positive rate was 3% among low-risk patients and 16% among high-risk patients. It also detected precancerous high-grade dysplasia in more than 64% of cases.
The test is designed to complement, rather than replace, existing diagnostic strategies by flagging high-risk patients for further evaluation, researchers said in the release.
Read the full study here.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
